Insider Selling: Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO Sells $27,415.00 in Stock

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT – Get Rating) CEO James F. Oliviero III sold 5,483 shares of the firm’s stock in a transaction that occurred on Thursday, March 2nd. The shares were sold at an average price of $5.00, for a total value of $27,415.00. Following the completion of the transaction, the chief executive officer now owns 144,090 shares of the company’s stock, valued at $720,450. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Checkpoint Therapeutics Stock Performance

Shares of CKPT stock opened at $5.20 on Monday. The firm’s 50-day moving average is $5.43 and its 200-day moving average is $2.86. The stock has a market cap of $48.36 million, a price-to-earnings ratio of -0.60 and a beta of 1.52. Checkpoint Therapeutics, Inc. has a 52-week low of $3.56 and a 52-week high of $19.50.

Analysts Set New Price Targets

Several equities analysts recently weighed in on CKPT shares. Lake Street Capital decreased their target price on shares of Checkpoint Therapeutics from $41.00 to $32.00 in a research note on Thursday. HC Wainwright restated a “buy” rating and set a $76.00 price objective on shares of Checkpoint Therapeutics in a research note on Thursday. Finally, B. Riley upped their target price on shares of Checkpoint Therapeutics from $7.00 to $15.00 and gave the company a “buy” rating in a report on Monday, December 19th.

Institutional Investors Weigh In On Checkpoint Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Envestnet Asset Management Inc. raised its holdings in shares of Checkpoint Therapeutics by 16.4% in the 1st quarter. Envestnet Asset Management Inc. now owns 77,800 shares of the company’s stock valued at $138,000 after purchasing an additional 10,953 shares during the period. Jane Street Group LLC raised its holdings in Checkpoint Therapeutics by 133.8% in the 2nd quarter. Jane Street Group LLC now owns 31,099 shares of the company’s stock valued at $32,000 after acquiring an additional 17,799 shares during the period. State Street Corp raised its holdings in Checkpoint Therapeutics by 9.6% in the 1st quarter. State Street Corp now owns 210,939 shares of the company’s stock valued at $373,000 after acquiring an additional 18,472 shares during the period. Eqis Capital Management Inc. bought a new position in Checkpoint Therapeutics in the 1st quarter valued at about $33,000. Finally, Apollon Wealth Management LLC raised its holdings in Checkpoint Therapeutics by 29.5% in the 2nd quarter. Apollon Wealth Management LLC now owns 98,095 shares of the company’s stock valued at $101,000 after acquiring an additional 22,360 shares during the period.

About Checkpoint Therapeutics

(Get Rating)

Checkpoint Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Its product portfolio includes CK-301, CK-101, CK-103, CK-302, and Anti-CAIX. The company was founded on November 10, 2014 and is headquartered in Waltham, MA.